DEVELOPMENT AND OPTIMIZATION OF SOLID DISPERSION OF PROPOLIS

Abstract

Propolisis mainly used as anti-inflammatory, antiulcer, antimicrobial, wound healing which was selected for the preparation of solid dispersion. However, poor aqueous solubility and low bioavailability restrict its therapeutic efficiency in various diseases. Hence it is required to improve the aqueous solubility and bioavailability of propolis to enhance its therapeutic efficiency. Solid dispersion is a pharmaceutical technology where one or more active pharmaceutical ingredients (APIs) are dispersed in an inert carrier matrix, typically a polymer. This enhances the solubility and bioavailability of poorly water-soluble drugs, leading improved therapeutic effects. Solid dispersion was made by solvent evaporation method by using PVP K30 and PVP as polymers. Solid dispersion were evaluated for solubility, FTIR, Percentage yield, Invitro drug release and DSC. The highest solubility was obtain for F6 solid dispersion which is 1.6times better then drug. FTIR shows the same peaks as of formulation of solid dispersion so no incompatibility issue with the excipients. The invitro release of pure drug was compared with formulation of solid dispersion and was found to be 81% and it shows the better release. Thus, Solid dispersion is a well-known approach for increasing the solubility and bioavailability of weakly water-soluble drugs. Therefore the best solid dispersion formulation of propolis is F6 formulation.